Abstract

Obesity, a multifactorial metabolic disorder characterized by excessive fat accumulation, has become a leading 
global health challenge. Recent research underscores the gut microbiome, a complex community of 
microorganisms inhabiting the human gastrointestinal tract as a crucial regulator of host metabolism, energy 
homeostasis, and inflammation. Dysbiosis, defined as an imbalance in microbial composition, has been closely 
associated with obesity and its related metabolic complications. Current evidence suggests that gut microbial 
diversity, diet, genetics, and environmental factors interact dynamically to influence weight gain and metabolic 
efficiency. Alterations in the Firmicutes/Bacteroidetes ratio, changes in short-chain fatty acid (SCFA) production, 
and modulation of bile acid metabolism highlight key mechanistic links between gut microbiota and obesity 
pathogenesis. Emerging studies emphasize the promise of microbiome-targeted interventions such as probiotics, 
prebiotics, fecal microbiota transplantation (FMT), and dietary modifications to restore microbial balance and 
improve metabolic health. However, methodological challenges, including small sample sizes, confounding factors, 
and data variability, limit the reproducibility and interpretation of findings. Longitudinal studies demonstrate that 
gut microbial diversity fluctuates following interventions such as bariatric surgery, reflecting the microbiome’s 
responsiveness to metabolic shifts. Personalized medicine approaches integrating gut microbial profiling, 
nutrigenetics, and omics-based analyses offer potential for individualized weight loss and disease prevention 
strategies. The public health implications of these findings are profound, as microbiome-informed interventions 
could provide low-cost, non-invasive strategies for obesity prevention and management. Nevertheless, ethical 
challenges, such as informed consent, data ownership, and commercialization of microbiome data demand careful 
governance to ensure equitable access and responsible innovation. To advance understanding, future research 
must prioritize large-scale, population-based longitudinal studies to establish causality, identify key microbial 
species, and evaluate the efficacy and safety of microbiome-based therapies. By bridging mechanistic insights with 
personalized and ethical applications, microbiome science holds transformative potential for obesity control and 
global metabolic health improvement.